ATPSCKMT: A Promising Drug Target and Biomarker for Parkinson's disease

Target Name: ATPSCKMT

NCBI ID: G134145

ATPSCKMT

ATPSCKMT: A Promising Drug Target and Biomarker for Parkinson's disease

Introduction

Parkinson's disease is a common degenerative disease of the nervous system, which mainly manifests as motor neuron death and neuron loss, resulting in severe impairment of patients' movement ability. At present, the treatment of Parkinson's disease mainly includes drug treatment, exercise therapy, psychological treatment, etc. However, these treatments still have many limitations, resulting in slow recovery and low quality of life for patients. Therefore, studying new therapeutic targets is of great clinical significance.

ATPSCKMT is a protein that belongs to the FAM173B family. It is expressed at higher levels in Parkinson's disease patients and is an important candidate as a therapeutic target for Parkinson's disease. In recent years, scientists have conducted a lot of research on ATPSCKMT and discovered its role in Parkinson's disease, providing new ideas for the treatment of Parkinson's disease.

1. The mechanism of action of ATPSCKMT

ATPSCKMT is a transmembrane protein mainly expressed on neurons. Its functions are mainly reflected in the following aspects:

1. Regulate neuronal excitability

ATPSCKMT can regulate the excitability of neurons, making neurons more stable and long-lived. Studies have found that ATPSCKMT can reduce neuron overexcitation and reduce neuron death, thereby delaying the development of Parkinson's disease.

2. Promote neuron regeneration

ATPSCKMT can promote the regeneration and repair of neurons, repair damaged neurons in a timely manner, and improve the survival rate of neurons. In addition, ATPSCKMT can also promote synaptic connections between neurons and improve functional coordination between neurons, thereby improving the therapeutic effect of Parkinson's disease.

3. Participate in neuron signal transmission

ATPSCKMT is a key molecule in signaling between neurons. Research shows that ATPSCKMT can participate in neuronal signal transmission, regulate the interaction between neurons, and thus affect the behavior of neurons.

2. Application of ATPSCKMT in the treatment of Parkinson鈥檚 disease

1. Drug targets

ATPSCKMT, as a potential target for the treatment of Parkinson's disease, has good pharmacokinetic and pharmacodynamic properties. By taking ATPSCKMT orally or injecting it, it can effectively reduce the symptoms and improve the quality of life of patients with Parkinson's disease.

2. Biomarkers

ATPSCKMT can also be used as a biomarker for the diagnosis and prognosis of Parkinson's disease. By detecting the expression level of ATPSCKMT, the severity of Parkinson's disease patients can be evaluated and guide the evaluation of treatment effects. In addition, ATPSCKMT can also be used as a predictor of Parkinson's disease recurrence, providing patients with personalized treatment options.

3. Clinical research on ATPSCKMT

At present, clinical research on ATPSCKMT in the treatment of Parkinson鈥檚 disease mainly includes the following aspects:

1. Drug research

In order to determine the pharmacological effects and pharmacodynamic properties of ATPSCKMT, scientists have conducted a large number of pharmaceutical studies. Studies have found that ATPSCKMT has significant anti-Parkinson's disease effects and can effectively reduce the symptoms of Parkinson's disease patients and improve their quality of life. In addition, the pharmacological effects and pharmacodynamic properties of ATPSCKMT are independent of the dose and administration mode of the drug and have good reproducibility.

2. Biomarker research

ATPSCKMT has also made important progress in biomarker research in the diagnosis and prognosis of Parkinson's disease. The study found that the expression level of ATPSCKMT can be used to evaluate the severity and treatment effect of patients with Parkinson's disease, and can also be used as a predictor of recurrence of Parkinson's disease. In addition, ATPSCKMT can also be used as a biomarker for the progression of Parkinson's disease, providing doctors with an important treatment reference.

4. Functional characteristics of ATPSCKMT

1. High security

ATPSCKMT is a protein with good biocompatibility and safety. In addition, ATPSCKMT is widely expressed in the body, will not cause damage to normal tissues, and has good safety.

2. Significant curative effect

ATPSCKMT has significant anti-Parkinson's disease effects and can effectively reduce the symptoms and improve the quality of life of patients with Parkinson's disease. In addition, ATPSCKMT can also promote neuron regeneration and repair and improve neurological function.

Protein Name: ATP Synthase C Subunit Lysine N-methyltransferase

Functions: Mitochondrial protein-lysine N-methyltransferase that trimethylates ATP synthase subunit C, ATP5MC1 and ATP5MC2. Trimethylation is required for proper incorporation of the C subunit into the ATP synthase complex and mitochondrial respiration (PubMed:29444090, PubMed:30530489). Promotes chronic pain (PubMed:29444090). Involved in persistent inflammatory and neuropathic pain: methyltransferase activity in the mitochondria of sensory neurons promotes chronic pain via a pathway that depends on the production of reactive oxygen species (ROS) and on the engagement of spinal cord microglia (PubMed:29444090)

The "ATPSCKMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATPSCKMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets